过去30年儿童狼疮性肾炎的临床、实验室、治疗特征与结局如何演变
该研究回顾性分析103例儿童起病的狼疮性肾炎(LN)患者,按LN诊断年份分为1993—2005年组和2006—2023年组,比较两组人口学、实验室、治疗特征及预后。结果显示组2完全肾脏缓解更常见,组1终末期肾病(ESKD)和死亡更常见;首次就诊时蛋白尿和SLEDAI评分是进展至ESKD的独立危险因素。
要点
- 组2完全肾脏缓解较组1更常见(P=0.005),组1 ESKD和死亡较组2更常见(P=0.005和P=0.001)。
- 组1基线SLEDAI评分更高、抗磷脂抗体阳性更频繁(P=0.040和P=0.025)。
- 首次就诊时蛋白尿和SLEDAI评分是进展至ESKD的独立危险因素(P=0.037和P=0.024)。
核心结论
- 过去多年儿童SLE的诊断和管理已有显著改善,表现为诊断更早、起病时疾病活动度更低和结局改善。
研究设计与样本
- 回顾性研究,纳入103例儿童起病的狼疮性肾炎患者,按LN诊断年份分为1993—2005年组(组1)和2006—2023年组(组2)。
主要发现
- 组1的SLE诊断平均年龄、LN诊断年龄、LN发生时间及诊断平均延迟时间均显著高于组2(分别为P<0.001、P<0.001、P=0.049和P=0.004)。
- 组1基线SLEDAI评分更高、抗磷脂抗体阳性更频繁(P=0.040和P=0.025)。
- 维持期硫唑嘌呤在组1更常用(P=0.016),利妥昔单抗在组2更常用(P=0.042)。
- 两组多数患者为增殖性LN(III类和/或IV类),组1为53.5%、组2为68%。
- 组2完全肾脏缓解较组1更常见(P=0.005),组1 ESKD和死亡较组2更常见(P=0.005和P=0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Management of systemic lupus erythematosus (SLE) through new treatment options has improved lupus nephritis (LN) prognosis. The aim of this study was to compare the changes in the demographic, laboratory, and treatment characteristics, prognosis, and outcomes of paediatric-onset LN patients over 30 years. METHODS: We retrospectively reviewed the medical records of 103 paediatric-onset LN patients. Patients were divided into two subgroups according to the years of LN diagnosis. Group 1 consisted of patients diagnosed with LN between the years of 1993 and 2005, and group 2 consisted of patients diagnosed with LN between the years of 2006 and 2023. RESULTS: The mean age at diagnosis of SLE, age at diagnosis of LN, time to LN development, and mean delay time to diagnosis were significantly higher in group 1 (P < 0.001, P < 0.001, P = 0.049, and P = 0.004, respectively). Baseline Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores were higher and anti-phospholipid antibody positivity was more frequent in group 1 (P = 0.040 and P = 0.025, respectively). Azathioprine in the maintenance phase was given more frequently in group 1 (P = 0.016), while rituximab was more frequently used in group 2 (P = 0.042). In both groups, the majority of the patients had proliferative LN (class III and/or class IV) (53.5% in group 1 vs. 68% in group 2). Complete renal remission was significantly more common in group 2 (P = 0.005), while end-stage kidney disease (ESKD) and death were significantly more common in group 1 (P = 0.005 and P = 0.001, respectively). Proteinuria and SLEDAI scores at the first visit were independent risk factors for progression to ESKD (P = 0.037 and P = 0.024). CONCLUSION: Over the years, there have been significant improvements in the diagnosis and management of children with SLE resulting in an earlier diagnosis, lower disease activity at onset, and improved outcomes.
引用
- Gezgin Yıldırım D, Karaçayır N, Kısaoğlu H, et al. How have the clinical, laboratory, treatment features and outcomes in children with lupus nephritis progressed over the last 30 years? Rheumatology (Oxford). 2025. PMID: 40108363. doi:10.1093/rheumatology/keaf151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。